Tryptamine Therapeutics Ltd

TYP

Company Profile

  • Business description

    Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

  • Contact

    C/o Bio101 Financial Advisory Pty Ltd
    697 Burke Road, Suite 201
    Camberwell
    MelbourneVIC3124
    AUS

    T: +61 390920475

    https://www.tryptherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    50

Stocks News & Analysis

stocks

Will China strong arm BHP into lower iron ore prices?

Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
stocks

Chart of the Week: Where Morningstar sees attractive dividend yields in 26/27

Charts from the Australian Dividend Outlook show the sectors where they are abundant.
stocks

2 picks in an undervalued ASX sector

Investors may be too pessimistic about this industry.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,287.109.40-0.10%
CAC 408,060.1385.281.07%
DAX 4024,597.13211.350.87%
Dow JONES (US)46,601.781.20-0.00%
FTSE 1009,548.8765.290.69%
HKSE26,829.46128.31-0.48%
NASDAQ23,043.38255.021.12%
Nikkei 22547,734.99215.89-0.45%
NZX 50 Index13,611.0942.610.31%
S&P 5006,753.7239.130.58%
S&P/ASX 2008,983.6011.40-0.13%
SSE Composite Index3,882.7820.250.52%

Market Movers